Geranylgeranylacetone as prevention for postoperative Atrial Fibrillation (GENIALITY trial)

Atrial fibrillation (AF) is the most common cardiac arrhythmia. Interestingly 30-50% of patients undergoing elective cardiothoracic surgery develop postoperative AF (PoAF). Unfortunately, preventive PoAF therapy is still suboptimal. In our previous studies we showed that cardioprotective heat shock protein (HSP) levels are increased by oral GeranylGeranylAcetone (GGA) administration. In line, GGA treatment protects against AF onset and progression in clinically relevant animal model studies.

To evaluate whether oral administration of GGA protects against incidence of PoAF on patients undergoing elective cardiothoracic surgery.

The trial is a phase II single-center, double-blind, placebo-controlled randomized trial. Participants (N=146) are adult patients, without any registered history of AF, undergoing elective open-heart surgery for mitral and/or valve repair, and/or coronary artery bypass grafting, are allocated with ratio 1:1 in treatment or placebo groups. Daily administration of 300mg of GGA or placebo starts five days before until three days after surgery. In order to assess cardiac rhythm, as primary endpoint, bedside cardiac monitoring is performed after surgery until hospital discharge. The patients undergo blood, right atrial appendage and epicardial adipose tissue sampling in order to assess proteostasis levels, as secondary endpoints.

The trial aims to reduce PoAF incidence in GGA group compared to placebo group, by increase of cardioprotective HSPs. Herewith, we expect to obtain proof of concept for a beneficial effect of GGA in preventing PoAF in patients undergoing cardiothoracic surgery.